Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3613351
Max Phase: Preclinical
Molecular Formula: C34H36N2O5
Molecular Weight: 552.67
Molecule Type: Small molecule
Associated Items:
ID: ALA3613351
Max Phase: Preclinical
Molecular Formula: C34H36N2O5
Molecular Weight: 552.67
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccccc1-c1ccc(C(=O)NCCNC(=O)c2ccc(O[C@H]3C4CC5CC3C[C@](C(=O)O)(C5)C4)cc2)cc1
Standard InChI: InChI=1S/C34H36N2O5/c1-21-4-2-3-5-29(21)23-6-8-24(9-7-23)31(37)35-14-15-36-32(38)25-10-12-28(13-11-25)41-30-26-16-22-17-27(30)20-34(18-22,19-26)33(39)40/h2-13,22,26-27,30H,14-20H2,1H3,(H,35,37)(H,36,38)(H,39,40)/t22?,26?,27?,30-,34-
Standard InChI Key: JNHUICIANQTFML-DVMICJFOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 552.67 | Molecular Weight (Monoisotopic): 552.2624 | AlogP: 5.48 | #Rotatable Bonds: 9 |
Polar Surface Area: 104.73 | Molecular Species: ACID | HBA: 4 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 4.05 | CX Basic pKa: | CX LogP: 5.59 | CX LogD: 2.47 |
Aromatic Rings: 3 | Heavy Atoms: 41 | QED Weighted: 0.31 | Np Likeness Score: -0.25 |
1. Pagire SH, Pagire HS, Lee GB, Han SJ, Kwak HJ, Kim JY, Kim KY, Rhee SD, Ryu JI, Song JS, Bae MA, Park MJ, Kim D, Lee DH, Ahn JH.. (2015) Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes., 101 [PMID:26218650] [10.1016/j.ejmech.2015.06.043] |
Source(1):